Colistimethate

drug
On this page

Also known as Colistin methanesulfonic acidColistin sulfomethateColistinmethanesulfonic acid

Summary

Colistimethate (CHEMBL6067483) is an approved unknown; indicated across 1 condition including osteomyelitis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Unknown
  • Indications: 1 condition
  • Clinical trials: 5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL6067483
NameColistimethate
TypeUnknown
Max phase4

Also known as: Colistimethate, Colistin methanesulfonic acid, Colistin sulfomethate, Colistinmethanesulfonic acid, colistimethate, COLISTIMETHATE

Parent form; salt/anhydrous children: CHEMBL1201441

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
osteomyelitis0MONDO:0005246EFO:0003102

Clinical trials

Total trials: 5.

Phase distribution

PhaseTrials
PHASE42
Not specified2
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01844778PHASE4COMPLETEDEase of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
NCT05586438PHASE4COMPLETEDPharmacokinetics of Colistin in Critically-ill Patients With AKI Who Receive SLED
NCT02452047PHASE3COMPLETEDEfficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
NCT06702943Not specifiedNOT_YET_RECRUITINGComparing Tigecycline Vs. Colistimethate in CNS Infections
NCT06834971Not specifiedRECRUITINGColistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.